Multiparametric MRI of the prostate

MRI

First and second year — the floor first, then every step

The DOMINANT sequence depends on the zone — diffusion in the peripheral zone, T2 in the transition zone — and getting that backwards inverts the score.

Orient first

  • Assessment is ZONE-DEPENDENT and this is the single most common source of error. In the PERIPHERAL zone, DWI/ADC is the dominant sequence and T2 is secondary. In the TRANSITION zone, T2 is dominant and DWI is secondary.
  • Dynamic contrast enhancement is a TIE-BREAKER, not a primary sequence: it upgrades an equivocal peripheral-zone lesion and does little else.
  • Suspicious peripheral-zone findings are focal, markedly hypointense on T2, with marked restriction — low ADC and high b-value signal — and a non-circumscribed shape.
  • In the transition zone, benign hyperplastic nodules are ENCAPSULATED and well-defined; a suspicious lesion is a lenticular or ill-defined homogeneous moderately hypointense area — the "erased charcoal" appearance.
  • HAEMORRHAGE after biopsy mimics and obscures tumour for weeks; T1-bright material in the gland must be recognised before scoring anything.

Acquire the study

  • High-resolution T2 in three planes, DWI with a high b-value and an ADC map, and dynamic contrast-enhanced sequences.
  • Wait an adequate interval after biopsy — commonly quoted as at least 6 weeks — because post-biopsy haemorrhage degrades the study.
  • Antispasmodic where available, and patient preparation to reduce rectal gas, which distorts the DWI at the posterior peripheral zone.
  • Confirm which sequence you are on before judging any signal — see the MRI sequence primer.
  • Check that the high b-value images are of usable quality before relying on them.

The manoeuvre

  • Review T1 FIRST for post-biopsy haemorrhage and note where it is.
  • Identify the zone of any lesion — peripheral, transition, central or anterior fibromuscular stroma — before scoring it.
  • For a PERIPHERAL zone lesion, score on DWI/ADC and use T2 as supporting; apply dynamic contrast only to an equivocal score.
  • For a TRANSITION zone lesion, score on T2 and use DWI as supporting.
  • Measure the lesion in its largest dimension on the sequence on which it is best seen, and say which sequence that was.
  • Assess EXTRAPROSTATIC EXTENSION: capsular bulge, irregularity, breach, and neurovascular bundle involvement.
  • Assess the seminal vesicles for low T2 signal and restricted diffusion.
  • Assess pelvic nodes and the visible bones — bone metastases are frequently visible and frequently missed on these studies.
  • Assign a category using a named system, state the version, and mark the lesion on a sector map.

What confirms it

  • A high-category lesion is one that is dominant on the ZONE-APPROPRIATE sequence and measures 1.5 cm or more, or shows definite extraprostatic extension.

What licenses you to exclude it

  • ⚠️ A negative study does not exclude clinically significant cancer, particularly anteriorly and in a large gland. State the residual risk rather than issuing an all-clear.
  • A study performed too soon after biopsy is degraded by haemorrhage and should be reported as limited, with a recommendation to repeat.
  • Severe rectal gas artefact on DWI makes the posterior peripheral zone non-diagnostic — say so rather than scoring it.

The classic misread

  • Scoring a transition-zone lesion on diffusion, or a peripheral-zone lesion on T2.
  • Scoring through post-biopsy haemorrhage.
  • Using dynamic contrast as a primary rather than a tie-breaking sequence.
  • Not looking at the bones.

Reference values

Each value carries the caveat that keeps it from being misused. Normal limits and diagnostic criteria are kept apart on purpose: a disease cut-off read as a normal range is the more dangerous mistake.

Normal limits

  • Prostate · Gland volume

    up to approximately 25–30 mL in the young adult

    Ellipsoid formula: length × width × height × 0.52, on transabdominal or transrectal ultrasound or T2-weighted MRI.

    Volume rises with age and the figure is a convention, not a disease boundary — symptoms and urodynamics define clinical significance, not millilitres alone.

    USG · MRI

Diagnostic criteria

  • Prostate · PSA density — how to report it

    serum PSA divided by gland volume; many pathways use about 0.15 ng/mL/mL as a discussion threshold, and the figure is pathway-specific

    PSAD = PSA (ng/mL) ÷ prostate volume (mL). Volume must use a stated formula (ellipsoid 0.52 is the usual imaging method) because the coefficient changes the density.

    ⚠️ 0.15 is a CONVENTION in several pathways, not a biological constant — name the pathway. A wrong volume formula silently invents a density. Versioned criterion — verify against the current edition before clinical use.

    USG · MRI

  • Prostate lesion · PI-RADS categorisation — how to report it

    a named criteria set: dominant-sequence scoring by zone; a lesion 15 mm or larger (or with extraprostatic extension) upgrades score 4 to 5

    Scoring is zone-specific — DWI leads in the peripheral zone, T2 in the transition zone — and applying the wrong dominant sequence is the classic error. Read the scoring tables from the current version. Versioned criterion — verify against the current edition before clinical use.

    MRI

See it on real cases

Direct links to Radiopaedia — the reference article and worked cases with their images. Each opens on Radiopaedia.

Key papers

Reviews and guidelines from RSNA, ESR and related journals. Each opens at its DOI.

  1. Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis ↗Oerther B, Nedelcu A, Engel H, et al. · Radiology 2024RSNA · PubMed
  2. PI-RADS version 2.1: one small step for prostate MRI ↗Barrett T, Rajesh A, Rosenkrantz AB, et al. · Clinical Radiology 2019RCR · PubMed
  3. Preoperative Prostate MRI: A Road Map for Surgery ↗McEvoy SH, Raeside MC, Chaim J, et al. · AJR 2018ARRS · PubMed
  4. Prostate MRI Qualification: AJR Expert Panel Narrative Review ↗Barrett T, Ghafoor S, Gupta RT, et al. · AJR 2022ARRS · PubMed

More searches

More in Abdomen and pelvis